COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question

Simply Wall St.

Yesterday

COMPASS Pathways (NasdaqGS:CMPS) is back in focus as investors watch the final stages of its planned FDA application for COMP360, a synthetic psilocybin treatment for people with treatment-resistant ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2662113637"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2662113637\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2662113637?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-26 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662113637","market":"hk","top_or_hot":-1,"title":"COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question","media":"Simply Wall St.","content":"<div>\n<p>COMPASS Pathways (NasdaqGS:CMPS) is back in focus as investors watch the final stages of its planned FDA application for COMP360, a synthetic psilocybin treatment for people with treatment-resistant ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-nears-fda-filing-for-comp360-following\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOMPASS Pathways (CMPS) Nears FDA Filing for COMP360 Following a Valuation Question\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-26 19:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-nears-fda-filing-for-comp360-following><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>COMPASS Pathways (NasdaqGS:CMPS) is back in focus as investors watch the final stages of its planned FDA application for COMP360, a synthetic psilocybin treatment for people with treatment-resistant ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-nears-fda-filing-for-comp360-following\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-nears-fda-filing-for-comp360-following","article_id":"2662113637","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/compass-pathways-cmps-nears-fda-filing-for-comp360-following","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2662113637","pubTimestamp":1787743564,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"COMPASS Pathways (NasdaqGS:CMPS) is back in focus as investors watch the final stages of its planned FDA application for COMP360, a synthetic psilocybin treatment for people with treatment-resistant depression.\nOver the past year, COMPASS Pathways has seen strong momentum, with a year to date share price return of 127.18% and a 1 year total shareholder return of 212.61%. The recent 32.15% 30 day share price return suggests that enthusiasm around the FDA submission is building further.\nScan...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LABU":"三倍做多标普生物-Direxion","CMPS":"COMPASS Pathways plc","PSIL":"AdvisorShares Psychedelics ETF"},"translate_title":"COMPASS Pathways (CMPS) 因估值问题接近 COMP360 向 FDA 申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"CMPS":1.5,"PSIL":0.6},"content_text":"COMPASS Pathways (NasdaqGS:CMPS) is back in focus as investors watch the final stages of its planned FDA application for COMP360, a synthetic psilocybin treatment for people with treatment-resistant depression. Over the past year, COMPASS Pathways has seen strong momentum, with a year to date share price return of 127.18% and a 1 year total shareholder return of 212.61%. The recent 32.15% 30 day share price return suggests that enthusiasm around the FDA submission is building further. Scan beyond COMPASS Pathways and compare this move in mental health biotech to a hand picked 18 high quality undiscovered gems that could be next in line for attention. After a move like this, COMPASS Pathways now asks investors a simple question: Does the potential reward for COMP360 and its late stage FDA push still justify the risks at today’s price, once you run the numbers? AdvertisementMost Popular Narrative: 39.2% Undervalued Based on the most widely followed narrative, COMPASS Pathways is priced at $14.88 against an estimated fair value of $24.47, which puts a spotlight on what is assumed for COMP360.  Completion of enrollment in the COMP006 Phase III trial and the plan to use 9 week data from Part A together with 26 week COMP005 data to support a rolling NDA process could shorten the path to potential approval, which would bring revenue forward and may support earlier earnings visibility.  Read the complete narrative. Read the complete narrative. Want to understand why this narrative still finds upside at this price? It leans on ambitious revenue ramps, rising margins and a rich future earnings multiple. Curious which assumptions really carry the valuation load? Result: Fair Value of $24.47 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, COMPASS Pathways still faces clinical and funding risks, including potential Phase III setbacks and the possibility of further dilution if cash needs exceed current resources. Find out about the key risks to this COMPASS Pathways narrative. Next Steps If this mix of optimism and concern around COMPASS Pathways feels familiar, treat it as a prompt to move quickly and test the numbers yourself. Weigh both sides of the story in detail by checking the 2 key rewards and 3 important warning signs. Looking for more investment ideas beyond COMPASS Pathways? If COMPASS Pathways has your attention, do not stop here. Broaden your watchlist now so you are not reacting late when the next story breaks.  Target future potential by reviewing 49 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their business strength. Prioritise stability and capital protection by checking a 74 resilient stocks with low risk scores that focuses on companies with more resilient risk profiles. Strengthen your foundation with a list of solid balance sheet and fundamentals (51 results) so you are backing businesses with healthier debt and liquidity positions.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}